Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Paxlovid  Treatment of COVID-19 on 7-may-22/I had a rebound in symptoms and tested positive after testing negative twice on 5/10 and 5/11; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Paxlovid  Treatment of COVID-19 on 7-may-22/I had a rebound in symptoms and tested positive after testing negative twice on 5/10 and 5/11) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Drug allergy (Allergy was reported as reaction of an unknown historical drug).   In December 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2022, the patient received dose of NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) 1 dosage form. On 15-May-2022 at 7:00 AM, the patient experienced COVID-19 (Paxlovid  Treatment of COVID-19 on 7-may-22/I had a rebound in symptoms and tested positive after testing negative twice on 5/10 and 5/11). At the time of the report, COVID-19 (Paxlovid  Treatment of COVID-19 on 7-may-22/I had a rebound in symptoms and tested positive after testing negative twice on 5/10 and 5/11) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 11-May-2022, SARS-CoV-2 test: negative (Negative) Negative. In May 2022, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication was reported.  The patient was not taking any other medications/products within two weeks of starting COVID-19 treatment. Patient had a rebound in symptoms on 15-May-2022 07:00. Patient was tested positive after testing negative twice on 10-May-2022 and on 11-May-2022.  Company Comment: This is a spontaneous case concerning  a  39-year-old, male patient with no relevant medical history, who experienced the unexpected AESI non-serious event of Covid-19. The event occurred on May 16, 2022, after the unspecified dose of mRNA-1273 COVID 19 Vaccine. Patient tested negative twice (May 10 and May 11) for SARS-CoV-2 test; Tested positive on May 16, 2022. Patient was treated Nirmatrelvir/ritonavir at an unspecified dose and frequency. The event was reported as not resolved. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.; Sender's Comments: Company Comment: This is a spontaneous case concerning  a  39-year-old, male patient with no relevant medical history, who experienced the unexpected AESI non-serious event of Covid-19. The event occurred on May 16, 2022, after the unspecified dose of mRNA-1273 COVID 19 Vaccine. Patient tested negative twice (May 10 and May 11) for SARS-CoV-2 test; Tested positive on May 16, 2022. Patient was treated Nirmatrelvir/ritonavir at an unspecified dose and frequency. The event was reported as not resolved. The benefit-risk relationship of mRNA-1273 COVID 19 Vaccine, is not affected by this report.